Trelegy Ellipta® 200 mcg (fluticasone furoate, umeclidinium, and vilanterol) is a once-daily prescription medication used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This inhaler combines three active ingredients—fluticasone furoate (a corticosteroid), umeclidinium (a long-acting muscarinic antagonist, or LAMA), and vilanterol (a long-acting beta-agonist, or LABA)—to provide comprehensive relief from COPD symptoms. The combination helps improve lung function, reduce inflammation, and prevent COPD flare-ups, thereby enhancing overall respiratory health and quality of life.

Features:

• Triple-Combination Therapy: Trelegy Ellipta® 200 mcg combines three active ingredients—fluticasone furoate (a corticosteroid), umeclidinium (a LAMA), and vilanterol (a LABA)—to address the multiple factors contributing to COPD symptoms. It helps reduce inflammation, prevent bronchoconstriction, and improve airflow, offering a well-rounded treatment option.

• FDA-Approved: Approved by the FDA for the maintenance treatment of COPD in adults. Trelegy Ellipta® is not for the relief of acute bronchospasm or sudden asthma attacks.

• Once-Daily Dosing: Trelegy Ellipta® is designed for once-daily use, with just one inhalation providing continuous symptom relief for 24 hours. This helps to reduce the burden of daily medication administration.

• Proven Effectiveness: Clinical studies show that Trelegy Ellipta® improves lung function, reduces exacerbations, and helps control daily COPD symptoms, such as wheezing, coughing, and shortness of breath.